Table of Contents

• What is Naldemedine?
• How Naldemedine Works
• Understanding Opioid-Induced Constipation
• Benefits of Naldemedine
• Dosage and Administration
• Clinical Research on Naldemedine
• Safety Profile and Side Effects
• Naldemedine in Special Populations
• Naldemedine Compared to Other Medications
• Future Research Directions

What is Naldemedine?

Naldemedine (also known by the brand names Symproic® and Rizmoic) is a medication specifically designed to treat opioid-induced constipation (OIC) in adults with chronic pain^[1]. It belongs to a class of drugs called peripherally acting mu-opioid receptor antagonists (PAMORAs). Unlike regular laxatives, naldemedine works directly on the cause of constipation that happens when patients take opioid pain medications^[2].

Naldemedine is typically available as a 0.2 mg tablet that is taken once daily with or without food^[3]. For children, it may also be available as an oral suspension, which makes it easier to administer to younger patients^[4].

How Naldemedine Works

To understand how naldemedine works, it’s important to first understand why opioid medications cause constipation. Opioids relieve pain by binding to receptors called mu-opioid receptors in the brain. However, these same receptors are also found throughout your digestive system. When opioids bind to these receptors in your gut, they slow down the natural movement of your intestines, reducing water secretion and making bowel movements difficult^[5].

Naldemedine specifically targets and blocks these mu-opioid receptors in your digestive tract, but an important feature is that it does not cross the blood-brain barrier. This means it works only in your gut and does not interfere with the pain-relieving effects of your opioid medication in your brain^[6]. By blocking the opioid receptors in your gut, naldemedine helps restore normal bowel function while allowing your pain medication to continue working effectively.

Understanding Opioid-Induced Constipation

Opioid-induced constipation (OIC) is a common side effect experienced by up to 90% of patients taking opioid medications for pain management^[6]. Unlike regular constipation, OIC occurs specifically because of how opioids affect your digestive system and often doesn’t respond well to standard laxative treatments.

Common symptoms of OIC include:

• Reduced frequency of bowel movements
• Hard, dry stools that are difficult to pass
• Straining during bowel movements
• Incomplete evacuation (feeling like you haven’t completely emptied your bowels)
• Abdominal bloating and discomfort
• Abdominal pain

OIC can significantly impact quality of life and may even cause some patients to reduce or stop their pain medication, which can lead to inadequate pain control^[2]. This is why treatments specifically targeting OIC, like naldemedine, are important for patients requiring long-term opioid therapy.

Benefits of Naldemedine

Clinical studies have shown several benefits of naldemedine for patients with opioid-induced constipation:

• Increased frequency of bowel movements: Research shows that naldemedine significantly increases the number of spontaneous bowel movements (bowel movements that occur without the use of rescue laxatives) per week compared to placebo^[2].
• Faster relief: Studies indicate that many patients experience their first spontaneous bowel movement within 24-48 hours after starting treatment with naldemedine^[5].
• Improved stool consistency: Naldemedine helps improve stool consistency, making bowel movements easier to pass^[7].
• Reduced straining: Patients taking naldemedine report less straining during bowel movements^[8].
• Better quality of life: By reducing constipation symptoms, naldemedine helps improve overall quality of life for patients on long-term opioid therapy^[1].
• Maintains pain relief: Because naldemedine doesn’t cross into the brain, it doesn’t interfere with the pain-relieving effects of opioid medications^[6].

Dosage and Administration

For adults with chronic non-cancer pain, the standard recommended dose of naldemedine is 0.2 mg taken orally once daily with or without food^[3]. The medication can be taken at any time of day, but taking it at the same time each day helps establish a routine.

For children, dosing is weight-based and may range from 0.05 mg to 0.2 mg. In pediatric patients, naldemedine may be administered either as tablets (for the 0.2 mg dose level only) or as an oral suspension (for all dose levels)^[4].

Important administration points:

• Naldemedine can be taken with or without food
• If you miss a dose, take it as soon as you remember. If it’s almost time for your next dose, skip the missed dose and continue with your regular schedule
• Do not take more than one dose in a 24-hour period
• Tablets should be swallowed whole and not crushed or chewed
• For patients who have difficulty swallowing tablets, an oral suspension may be available through your healthcare provider

Clinical Research on Naldemedine

Naldemedine has been extensively studied in multiple clinical trials to evaluate its efficacy and safety for treating opioid-induced constipation.

Short-Term Efficacy Studies

Several 12-week studies have demonstrated that naldemedine significantly improves bowel function in patients with OIC. In these studies, participants receiving naldemedine were more likely to have regular, spontaneous bowel movements compared to those receiving placebo^[8]. The studies measured what’s called a “responder,” defined as a person who had at least 3 spontaneous bowel movements per week and an increase of at least 1 spontaneous bowel movement from their baseline^[2].

Long-Term Safety Studies

A 52-week study evaluated the long-term safety of naldemedine. This study showed that naldemedine maintained its effectiveness over the extended period and did not lead to significant withdrawal symptoms or loss of pain control in patients taking opioids^[1]. Importantly, the long-term use of naldemedine continued to show improvements in quality of life measurements related to constipation symptoms^[1].

Dose-Finding Studies

Early research on naldemedine tested various doses ranging from 0.1 mg to 0.4 mg. These studies helped determine that the 0.2 mg dose provides the optimal balance of efficacy and safety for most patients^[7]. Lower doses (0.1 mg) showed less efficacy, while higher doses (0.4 mg) did not provide significant additional benefits but had a slightly higher rate of side effects^[7].

Research on Special Uses

Beyond treating OIC, naldemedine is being studied for other potential uses. For example, one study is investigating naldemedine’s effects on gastrointestinal recovery following surgeries that include bowel resection or transection^[9]. Another study is exploring whether naldemedine can help prevent opioid-induced nausea and vomiting in patients with cancer starting opioid analgesics^[10]. Additional research is examining its potential benefits in recurrent acute pancreatitis^[11].

Safety Profile and Side Effects

Clinical trials have shown that naldemedine is generally well-tolerated, but like all medications, it can cause side effects in some patients.

Common Side Effects

The most common side effects reported in clinical trials include^[1]:

• Abdominal pain: This is typically mild to moderate and tends to decrease over time as your body adjusts to the medication
• Diarrhea: Some patients experience loose stools, especially when first starting treatment
• Nausea: Feelings of queasiness may occur, particularly during the initial days of treatment
• Vomiting: Less common than nausea but can occur in some patients
• Gastroenteritis: Inflammation of the stomach and intestines causing discomfort

Most of these side effects are mild to moderate and often improve after the first week of treatment as your body adjusts to the medication^[1].

Serious Side Effects

Though rare, more serious side effects can occur and require immediate medical attention^[5]:

• Opioid withdrawal symptoms: Though uncommon since naldemedine doesn’t cross the blood-brain barrier, some patients may experience symptoms like sweating, chills, diarrhea, stomach pain, anxiety, irritability, and yawning
• Gastrointestinal perforation: Very rare but serious, this is more likely in patients with certain gastrointestinal conditions or taking medications that may increase the risk

Drug Interactions

Naldemedine may interact with certain medications^[7]:

• Strong CYP3A inhibitors (like clarithromycin, ketoconazole, or grapefruit juice): These may increase naldemedine levels in your body
• Strong CYP3A inducers (like rifampin, carbamazepine, or St. John’s wort): These may decrease naldemedine levels and make it less effective
• P-glycoprotein inhibitors (like cyclosporine): These may increase naldemedine exposure

Always inform your healthcare provider about all medications, supplements, and herbal products you are taking before starting naldemedine.

Naldemedine in Special Populations

Pediatric Patients

Research on naldemedine use in children is ongoing. A current clinical trial is evaluating the pharmacokinetics, safety, and tolerability of naldemedine in pediatric patients who are receiving opioids^[4]. This study involves different age cohorts, starting with adolescents (≥12 to <18 years) and progressively including younger children (≥6 to <12 years, and then ≥2 to <6 years) as safety is established. For children, the medication may be administered as an oral tablet (0.2 mg dose level only) or as an oral suspension (all dose levels)^[4].

Elderly Patients

Clinical studies have included patients over 65 years of age, and no dose adjustment is generally necessary for elderly patients based solely on age. However, as kidney and liver function may decline with age, monitoring for side effects may be more important in this population^[1].

Patients with Liver or Kidney Impairment

For patients with mild to moderate liver impairment, no dose adjustment is typically required. However, naldemedine has not been extensively studied in patients with severe liver impairment. Similarly, patients with mild to moderate kidney impairment usually don’t need dose adjustments, but those with severe kidney impairment should be monitored more closely^[1].

Naldemedine Compared to Other Medications

Several medications are available to treat opioid-induced constipation. Understanding how naldemedine compares to these alternatives can help patients and healthcare providers make informed decisions.

Comparison with Other PAMORAs

Naldemedine belongs to the same class of medications (PAMORAs) as naloxegol (Movantik®) and methylnaltrexone (Relistor®). All three work by blocking opioid receptors in the gut without affecting pain relief. Some differences include:

• Administration: Naldemedine and naloxegol are taken orally once daily, while methylnaltrexone may be given as an injection or oral tablet
• Food interactions: Naldemedine can be taken with or without food, while naloxegol should be taken on an empty stomach
• Cardiovascular safety: A study is currently investigating the comparative cardiovascular safety of naldemedine versus other OIC medications^[3]

Comparison with Traditional Laxatives

Unlike traditional laxatives (such as stimulant laxatives, stool softeners, or osmotic agents), naldemedine addresses the specific mechanism of opioid-induced constipation by targeting opioid receptors in the gut. Traditional laxatives work through different mechanisms:

• Stimulant laxatives (like bisacodyl): Increase intestinal contractions
• Stool softeners (like docusate): Make stool softer by increasing water content
• Osmotic laxatives (like polyethylene glycol): Draw water into the intestine
• Bulk-forming laxatives (like psyllium): Add bulk to stool to stimulate bowel movements

While traditional laxatives may provide some relief, they often don’t fully address OIC because they don’t target the underlying mechanism. Naldemedine may be more effective for OIC because it specifically blocks the effects of opioids on the gut^[2].

Studies have shown that many patients with OIC continue to experience constipation despite using traditional laxatives, suggesting that medications like naldemedine may provide better relief for these patients^[8].

Future Research Directions

Research on naldemedine continues to explore its potential benefits beyond treating OIC in patients with chronic non-cancer pain.

Expanded Applications

Several ongoing and planned studies are investigating naldemedine for:

• Postoperative gastrointestinal recovery: A study is examining whether naldemedine can improve recovery of gastrointestinal function following surgeries involving bowel resection or transection^[9]
• Opioid-induced nausea and vomiting: Research is exploring whether naldemedine can help prevent opioid-induced nausea and vomiting in patients starting opioid analgesics for cancer pain^[10]
• Pediatric populations: Studies are ongoing to establish safety, efficacy, and appropriate dosing for children who require opioid therapy^[4]
• Recurrent acute pancreatitis: Investigation into whether naldemedine can reduce disease recurrence and progression in patients with recurrent acute pancreatitis^[11]
• Opioid-induced bowel dysfunction: Beyond constipation, research is looking at how naldemedine affects the broader spectrum of gastrointestinal issues caused by opioids^[6]

Long-term Outcomes

Future research will likely continue to evaluate the long-term safety and efficacy of naldemedine, particularly focusing on:

• Long-term impact on quality of life for patients requiring chronic opioid therapy
• Potential effects on opioid dosing requirements and pain management
• Safety outcomes with extended use beyond the current studies of up to 52 weeks
• Comparative effectiveness against other PAMORAs and traditional laxatives

As research continues, our understanding of how best to use naldemedine will continue to evolve, potentially offering more patients relief from the challenging side effects of opioid therapy while maintaining effective pain control.